The BTK inhibitor becomes the first of its class cleared for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

Karl Deisseroth, Peter Hegemann and Georg Nagel share the award for light-gated ion channels, a tool now central to neuroscience and experimental blindness and

The next-generation shot matched rival vaccines on nearly all bacterial strains in the first of three late-stage trials, lifting the biotech's shares.

The pact adds to a wave of Western pharma deals for Chinese biotech assets.

Phase 2 data showing a 46% response rate prompted Genmab to claim its ADC is clearly superior to AbbVie's Elahere.

A late-stage melanoma vaccine win has the field debating whether mRNA platforms can extend to other cancers.

The deal hands Shionogi a marketed treatment for two inherited conditions and expands its rare disease business.

AstraZeneca, Daiichi Sankyo and Summit will test the drug in combination studies after a $2 billion investment.

The readout supports the combination's use in blood cancers.

The agency's concerns centered on the manufacturing site rather than the drug's trial results.

A single-trial regulatory path could shorten development for the RNA editing candidate.

The alignment sets out a path toward registration for the Dravet syndrome candidate.

The case concerns RADV audit methodology and its financial exposure for insurers such as Humana.

The collaboration advances an ORIC oncology candidate through UK-led clinical development.

The request signals regulatory interest in psychedelic-adjacent treatments for addiction and mental health.

The conference will feature key questions on antibody-drug conjugates and other oncology modalities.

Investors reacted to progress toward commercialization of the multi-cancer early detection test.

The approval covers a drug-coated balloon for a common coronary artery complication.